search
Back to results

Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose

Primary Purpose

Ischemic Heart Disease, Aortic Aneurysm

Status
Unknown status
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Humulin R
Normal Saline
Sponsored by
Hiroaki Sato, MD., PhD.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Ischemic Heart Disease focused on measuring Intranasal Insulin, Insulin concentration, Blood glucose, Cerebro Spinal Fluid insulin, Intraoperative blood glucose, Cardiac Surgery, Thoracic Surgery

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

All patients (>18 years) undergoing elective open heart surgery requiring CPB or elective endovascular thoracic aortic aneurysm repair at the RVH.

Exclusion Criteria:

  1. Planned use of drugs that effect plasma glucose concentration during the first four hours of surgery.
  2. Patients with allergy to insulin
  3. Patients with a base line blood glucose less than 3.9 mmol/L

Sites / Locations

  • Royal Victoria Hospital McGill University Health CentreRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Intranasal 40

Intranasal 80

Placebo

Arm Description

Patients will receive 40 IU of intranasal insulin (Humulin R) via a metered nasal dispenser

Patients will receive 80 IU of intranasal insulin (Humulin R) via a metered nasal dispenser

Patients will receive intranasal normal saline via a metered nasal dispenser

Outcomes

Primary Outcome Measures

Blood Glucose
Arterial blood samples will be collected every 10 to 30 minutes during the surgery. Circulating concentrations of glucose will be measured.
Plasma Insulin
Arterial blood samples will be collected every 10 to 30 minutes during the surgery. Plasma insulin will be measured.
Cerebrospinal Fluid Insulin
Cerebrospinal Fluid will be taken every 10 to 30 minutes during the endovascular thoracic aneurysm repair surgery. Insuring concentration of Cerebrospinal fluid will be measured.

Secondary Outcome Measures

Full Information

First Posted
March 31, 2016
Last Updated
February 23, 2021
Sponsor
Hiroaki Sato, MD., PhD.
search

1. Study Identification

Unique Protocol Identification Number
NCT02729064
Brief Title
Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose
Official Title
Effect of Intranasal Insulin Administration on Glycaemia and Insulin Concentrations in Plasma and Cerebrospinal Fluid During Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
September 2016 (Actual)
Primary Completion Date
September 2021 (Anticipated)
Study Completion Date
September 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Hiroaki Sato, MD., PhD.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Intranasal insulin is reported to improves memory performance in patients suffering from cognitive impairment. The investigators have previously shown that intraoperative insulin administration preserves both short and long-term memory function after cardiac surgery. Applying intranasal insulin bypasses blood-brain barrier and cause elevation of insulin concentrations in the cerebrospinal fluid without major effects on peripheral insulin level. Patients undergoing major surgery are exposed to carbohydrate and insulin metabolism alteration. The goal of the study is to study the effect of intranasal insulin on blood glucose, plasma and cerebrospinal insulin concentration in patients undergoing cardiac surgery or endovascular thoracic aneurysm repair.
Detailed Description
Clinical trials have demonstrated that intranasal insulin improves both memory performance and metabolic integrity of the brain in patients suffering from Alzheimer's disease or cognitive impairment. A single dose of intranasal insulin acutely improved memory in memory-impaired older adults. Cognitive impairment in post-operative period is an increasing problem as more elderly patients undergo major surgery. The investigators have previously shown that intraoperative insulin administration while maintaining normoglycaemia preserves both short and long-term memory function after open heart surgery. Applying insulin as a nasal spray bypasses blood-brain barrier and cause significant and sustained elevation of insulin concentrations in the cerebrospinal fluid (CSF) without major effects on peripheral insulin levels. The administration of 40 IU of intranasal insulin(INI) rapidly increases CSF insulin concentration within seven minutes, peaking after 30 minutes and remaining elevated for more than 80 minutes. Presently it is not clear if CNS insulin plays a relevant role in controlling blood glucose in humans. Patients undergoing major surgery are exposed to metabolic and endocrine alterations in carbohydrate, protein, and insulin metabolism, often summarized as the catabolic stress response. While the effect of intravenous insulin on glucose metabolism during surgery has been extensively studied the influence of intranasal insulin administration on intraoperative plasma insulin and blood glucose concentrations is unknown. Goal and Objectives The goal of the present study is to study the effect of intranasal insulin on blood glucose and plasma insulin concentrations in patients undergoing elective cardiac surgery blood glucose, plasma insulin and cerebrospinal insulin concentration in patients undergoing elective endovascular thoracic aneurysm repair.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemic Heart Disease, Aortic Aneurysm
Keywords
Intranasal Insulin, Insulin concentration, Blood glucose, Cerebro Spinal Fluid insulin, Intraoperative blood glucose, Cardiac Surgery, Thoracic Surgery

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
141 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intranasal 40
Arm Type
Experimental
Arm Description
Patients will receive 40 IU of intranasal insulin (Humulin R) via a metered nasal dispenser
Arm Title
Intranasal 80
Arm Type
Experimental
Arm Description
Patients will receive 80 IU of intranasal insulin (Humulin R) via a metered nasal dispenser
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Patients will receive intranasal normal saline via a metered nasal dispenser
Intervention Type
Drug
Intervention Name(s)
Humulin R
Intervention Description
Study subjects will receive intranasal insulin (Humulin R) via a metered nasal dispenser.
Intervention Type
Drug
Intervention Name(s)
Normal Saline
Intervention Description
Study subjects will receive intranasal placebo (normal saline) via a metered nasal dispenser.
Primary Outcome Measure Information:
Title
Blood Glucose
Description
Arterial blood samples will be collected every 10 to 30 minutes during the surgery. Circulating concentrations of glucose will be measured.
Time Frame
During Surgery
Title
Plasma Insulin
Description
Arterial blood samples will be collected every 10 to 30 minutes during the surgery. Plasma insulin will be measured.
Time Frame
During Surgery
Title
Cerebrospinal Fluid Insulin
Description
Cerebrospinal Fluid will be taken every 10 to 30 minutes during the endovascular thoracic aneurysm repair surgery. Insuring concentration of Cerebrospinal fluid will be measured.
Time Frame
During Surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients (>18 years) undergoing elective open heart surgery requiring CPB or elective endovascular thoracic aortic aneurysm repair at the RVH. Exclusion Criteria: Planned use of drugs that effect plasma glucose concentration during the first four hours of surgery. Patients with allergy to insulin Patients with a base line blood glucose less than 3.9 mmol/L
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hiroaki Sato, MD., PhD.
Phone
+15149341934
Ext
36717
Email
hiroaki.sato2@mcgill.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Thomas Schricker, MD., PhD.
Phone
+15149341934
Ext
34883
Email
thomas.schricker@mcgill.ca
Facility Information:
Facility Name
Royal Victoria Hospital McGill University Health Centre
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4A 3J1
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hiroaki Sato, MD., PhD.
Phone
5149341934
Ext
36717
Email
hiroaki.sato2@mcgill.ca

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33721199
Citation
Roque P, Nakadate Y, Sato H, Sato T, Wykes L, Kawakami A, Yokomichi H, Matsukawa T, Schricker T. Intranasal administration of 40 and 80 units of insulin does not cause hypoglycemia during cardiac surgery: a randomized controlled trial. Can J Anaesth. 2021 Jul;68(7):991-999. doi: 10.1007/s12630-021-01969-5. Epub 2021 Mar 15.
Results Reference
derived
PubMed Identifier
30895515
Citation
Nakadate Y, Sato H, Roque P, Sato T, Matsukawa T, Wykes L, Kawakami A, Schricker T. Accuracy of blood glucose measurements using the NOVA StatStrip(R) glucometer during cardiac surgery: a prospective observational study. Can J Anaesth. 2019 Aug;66(8):943-952. doi: 10.1007/s12630-019-01350-7. Epub 2019 Mar 20.
Results Reference
derived

Learn more about this trial

Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose

We'll reach out to this number within 24 hrs